January 25, 2022 Recently, two institutions in the Down Syndrome Clinical Trials Network (DS-CTN) published five studies about Down syndrome-related health and
Impaired immune function is a clear and growing threat to the health and well-being of people with Down syndrome (DS).
January 12, 2022 During the past year, LuMind IDSC remained cautiously optimistic about treatment possibilities that the development of new drugs
RELIABLE DOWN SYNDROME RESOURCES FOR EVERY FAMILY, FOR EVERY STAGE OF LIFE “Down syndrome research is of huge importance to
2021 was a year of growth for LuMind IDSC. Thanks to donors like you, we were able to expand our
T21RS statement regarding COVID-19 booster vaccination for individuals with Down syndrome.Click to visit the T21RS site[image_with_animation image_url=”14923″ image_size=”full” animation_type=”entrance” animation=”None” animation_movement_type=”transform_y”
Dr. Marcia Ratner & Dr. James Hendrix discuss recent developments in Alzheimer’s research. Source: Dr. Marcia Ratner and Dr. James
In June of 2021, the FDA approved a new drug, Aduhelm, from the company Biogen for the treatment of mild
October 18, 2021 October is Down Syndrome Awareness Month, and to commemorate it, Hampus Hillerstrom, LuMind IDSC’s CEO, wrote an
October 18, 2021 Dr. Nicole White, Hampus Hillerstrom, LuMind IDSC and a team of experts, recently published an article in
